ABN 912

Drug Profile

ABN 912

Alternative Names: ABN912; Anti-MCP-1 monoclonal antibody

Latest Information Update: 16 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (IV-infusion)
  • 16 Jul 2010 Discontinued - Phase-I for Asthma in USA (unspecified route)
  • 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the adverse events and Rheumatic disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top